Search

Your search keyword '"Dorval, T"' showing total 327 results
Start Over Author "Dorval, T"
327 results on '"Dorval, T"'

1. Bias Image Correction Via Stationarity Maximization

Author

Dorval, T., Ogier, A., Genovesio, A., Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Doug, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Ayache, Nicholas, editor, Ourselin, Sébastien, editor, and Maeder, Anthony, editor

Published
2007
Full Text
View/download PDF

3. Is Primary Chemotherapy Useful for All Patients with Primary Invasive Breast Cancer?

Author

Scholl, S. M., Beuzeboc, P., Harris, A. L., Pierga, J. Y., Asselain, B., Palangié, T., Dorval, T., Jouve, M., Diéras, V., Pouillart, P., Schlag, P. M., editor, Senn, H.-J., editor, Diehl, V., editor, Parkin, D. M., editor, Rajewsky, M. F., editor, Rubens, R., editor, Wannenmacher, M., editor, Senn, Hans-Jörg, editor, Gelber, Richard D., editor, Goldhirsch, Aron, editor, and Thürlimann, Beat, editor

Published
1998
Full Text
View/download PDF

4. IMI European Lead Factory - democratizing access to high-throughput screening

Author

Jones, P.S., Boucharens, S., McElroy, S.P., Morrison, A., Honarnejad, S., Boeckel, S. van, Hurk, H. van den, Basting, D., Huser, J., Jaroch, S., Ottow, E., Benningshof, J., Folmer, R.H.A., Leemhuis, F., Kramer-Verhulst, P.M., Nies, V.J.M., Orrling, K.M., Rijnders, T., Pfander, C., Engkvist, O., Pairaudeau, G., Simpson, P.B., Ortholand, J.Y., Roche, D., Domling, A., Kuhnert, S.M., Roevens, P.W.M., Vlijmen, H. van, Wanrooij, E.J.A. van, Verbruggen, C., Nussbaumer, P., Ovaa, H., Stelt, M. van der, Simonsen, K.B., Tagmose, L., Waldmann, H., Duffy, J., Finsinger, D., Jurzak, M., Burgess-Brown, N.A., Lee, W.H., Rutjes, F., Haag, H., Kallus, C., Mors, H., Dorval, T., Lesur, B., Ramon Olayo, F., Hamza, D., Jones, G., Pearce, C., Piechot, A., Tzalis, D., Clausen, M.H., Davis, J, Derouane, D., Vermeiren, C., Kaiser, M., Stockman, R.A., Barrault, D.V., Pannifer, A.D., Swedlow, J.R., Nelson, A.S., Orru, R.V.A., Ruijter, E., Helden, S.P. van, Li, V.M., Vries, T. de, Vlieger, J.S.B. de, Jones, P.S., Boucharens, S., McElroy, S.P., Morrison, A., Honarnejad, S., Boeckel, S. van, Hurk, H. van den, Basting, D., Huser, J., Jaroch, S., Ottow, E., Benningshof, J., Folmer, R.H.A., Leemhuis, F., Kramer-Verhulst, P.M., Nies, V.J.M., Orrling, K.M., Rijnders, T., Pfander, C., Engkvist, O., Pairaudeau, G., Simpson, P.B., Ortholand, J.Y., Roche, D., Domling, A., Kuhnert, S.M., Roevens, P.W.M., Vlijmen, H. van, Wanrooij, E.J.A. van, Verbruggen, C., Nussbaumer, P., Ovaa, H., Stelt, M. van der, Simonsen, K.B., Tagmose, L., Waldmann, H., Duffy, J., Finsinger, D., Jurzak, M., Burgess-Brown, N.A., Lee, W.H., Rutjes, F., Haag, H., Kallus, C., Mors, H., Dorval, T., Lesur, B., Ramon Olayo, F., Hamza, D., Jones, G., Pearce, C., Piechot, A., Tzalis, D., Clausen, M.H., Davis, J, Derouane, D., Vermeiren, C., Kaiser, M., Stockman, R.A., Barrault, D.V., Pannifer, A.D., Swedlow, J.R., Nelson, A.S., Orru, R.V.A., Ruijter, E., Helden, S.P. van, Li, V.M., Vries, T. de, and Vlieger, J.S.B. de

Abstract

Contains fulltext : 252474.pdf (Publisher’s version ) (Open Access)

Published
2022

16. Interferons in Breast Cancer

Author

Dorval, T., Beuzeboc, P., Falcoff, E., Garcia-Giralt, E., Jouve, M., Palangie, T., Pouillart, P., Becker, Yechiel, editor, Hadar, Julia, editor, and Revel, Michel, editor

Published
1988
Full Text
View/download PDF

17. An Intensive Chemo- or Chemoimmunotherapy Regimen for Patients with Intermediate and Poor-Prognosis Acute Lymphatic Leukemia and Leukemic Lymphoblastic Lymphosarcoma: Preliminary Results with 14-Month Median Follow-Up

Author

Misset, J. L., De Vassal, F., Delgado, M., Ribaud, P., Musset, M., Dorval, T., Machover, D., Jasmin, C., Hayat, M., Schwarzenberg, L., Mathe, G., Allfrey, V. G., editor, Allgöwer, M., editor, Berenblum, I., editor, Bergel, F., editor, Bernard, J., editor, Bernhard, W., editor, Blokhin, N. N., editor, Bock, H. E., editor, Braun, W., editor, Bucalossi, P., editor, Chaklin, A. V., editor, Chorazy, M., editor, Cunningham, G. J., editor, Porta, G. Della, editor, Denoix, P., editor, Dulbecco, R., editor, Eagle, H., editor, Eker, R., editor, Good, R. A., editor, Grabar, P., editor, Harris, R. J. C., editor, Hecker, E., editor, Herbeuval, R., editor, Higginson, J., editor, Hueper, W. C., editor, Isliker, H., editor, Kieler, J., editor, Kirsten, W. H., editor, Klein, G., editor, Koprowski, H., editor, Koss, L. G., editor, Macbeth, R. A., editor, Martz, G., editor, Mathé, G., editor, Mühlbock, O., editor, Old, L. J., editor, Potter, V. R., editor, Sabin, A. B., editor, Sachs, L., editor, Saxén, E. A., editor, Schmidt, C. G., editor, Spiegelman, S., editor, Szybalski, W., editor, Tagnon, H., editor, Tissières, A., editor, Uehlinger, E., editor, Wissler, R. W., editor, Rentchnick, P., editor, Senn, H. J., editor, Bonadonna, G., editor, and Salmon, S., editor

Published
1982
Full Text
View/download PDF

19. BIAS FREE FEATURES DETECTION FOR HIGH CONTENT SCREENING

Author

Dorval, T., Ogier, Arnaud, Dusch, E., Emans, N., Kim, Hee-Young, Li, Xiaolan, and Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
INDEX TERMS Image Analysis, Microscope, Computer science, Confocal, [SDV]Life Sciences [q-bio], Feature extraction, ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION, 02 engineering and technology, Iterative reconstruction, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, 01 natural sciences, law.invention, Image (mathematics), Optical microscope, law, Object Detection, 0202 electrical engineering, electronic engineering, information engineering, Computer vision, [INFO]Computer Science [cs], Image retrieval, Biomedical Image Pro- cessing, business.industry, Biomedical Microscopy, Process (computing), Image Enhancement, 0104 chemical sciences, 010404 medicinal & biomolecular chemistry, High-content screening, 020201 artificial intelligence & image processing, Artificial intelligence, business
Abstract

International audience; Recent automated confocal microscopes used in High Content Screening (HCS) platforms require fully automated quantitative analysis due to the large amount of images they produce. Tuning the imaging process can not be manually performed on each image, therefore these automated acquisitions may come along with strong illumination artifacts due to poor physical imaging conditions. Such artifacts obviously have direct consequences on the efficiency of the image analysis algorithms but also on the quantitative measures. In this paper , we propose a method robust to illumination artifacts to extract any kind of small and isotropic objects within cells. To do so, we include a pre-processing step where a bias correction algorithm first attempts to retrieve original images from corrupted observations. We validate our framework with two different and independent statistical criteria.

Published
2007
Full Text
View/download PDF

20. Long-Term Administration of Vindesine in Maintenance Regimen for Acute Lymphoblastic Leukemia (ALL) with Poor Prognosis. Apparent Lack of Long-Term Cumulative Neurotoxicity

Author

Misset, J. L., primary, Mathé, G., additional, de Vassal, F., additional, Delgado, M., additional, Musset, M., additional, Metral, S., additional, Ropert, A., additional, Schwarzenberg, L., additional, Jasmin, C., additional, Machover, D., additional, Ribaud, P., additional, Dorval, T., additional, and Bayat, M., additional

Published
1981
Full Text
View/download PDF

22. Detection of Precancerous Bronchus Metaplasia in Heavy Smokers and Its Regression following Retinoid Treatment1

Author

Math�, G., primary, Gouveia, J., additional, Hercend, T., additional, Gros, F., additional, Dorval, T., additional, Hazon, J., additional, Misset, J. L., additional, Schwarzenberg, L., additional, Ribaud, P., additional, Lemaigre, G., additional, Santelli, G., additional, Homasson, J. P., additional, Gaillard, J. P., additional, Angebault, M., additional, Bonniot, J. P., additional, Lededente, A., additional, Marsac, J., additional, Parrot, R., additional, and Pretet, S., additional

Full Text
View/download PDF

24. Bevacizumab and Paclitaxel As First Line Chemotherapy of Her2 Negative Advanced Breast Cancer (Abc): Results of an Observational Institutional Study

Author

Pop, S., primary, Dujaric, M., additional, Beuzeboc, P., additional, Mignot, L., additional, Cottu, P.H., additional, Scholl, S., additional, Le Tourneau, C., additional, Dorval, T., additional, Piperno-Neumann, S., additional, Laurence, V., additional, Asselain, B., additional, Pierga, J., additional, and Dieras, V., additional

Published
2014
Full Text
View/download PDF

25. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

Author

UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - MD/MINT - Département de médecine interne, UCL - MD/BICL - Département de biochimie et de biologie cellulaire, van Baren, Nicolas, Bonnet, Marie-Claude, Dréno, B., Khammari, A, Dorval, T, Piperno-Neumann, S, Lienard, D., Speiser, David, Marchand, Marie, Brichard, Vincent G., Escudier, B, Negrier, S, Dietrich, PY, Maraninchi, D., Osanto, S, Meyer, RG, Ritter, G., Moingeon, P, Tartaglia, J, van der Bruggen, Pierre, Coulie, Pierre, Boon, Thierry, UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - MD/MINT - Département de médecine interne, UCL - MD/BICL - Département de biochimie et de biologie cellulaire, van Baren, Nicolas, Bonnet, Marie-Claude, Dréno, B., Khammari, A, Dorval, T, Piperno-Neumann, S, Lienard, D., Speiser, David, Marchand, Marie, Brichard, Vincent G., Escudier, B, Negrier, S, Dietrich, PY, Maraninchi, D., Osanto, S, Meyer, RG, Ritter, G., Moingeon, P, Tartaglia, J, van der Bruggen, Pierre, Coulie, Pierre, and Boon, Thierry

Abstract

Purpose To evaluate the toxicity, antitumoral effectiveness, and immunogenicity of repeated vaccinations with ALVAC miniMAGE-1/3, a recombinant canarypox virus containing a minigene encoding antigenic peptides MAGE-3(168-176) and MAGE-1(161-169), which are presented by HLA-A1 and B35 on tumor cells and can be recognized by cytolytic T lymphocytes (CTLs). Materials and Methods The vaccination schedule comprised four sequential injections of the recombinant virus, followed by three booster vaccinations with the MAGE-3(168-176) and MAGE-1(161-169) peptides. The vaccines were administered, both intradermally and subcutaneously, at 3-week intervals. Results Forty patients with advanced cancer were treated, including 37 melanoma patients. The vaccines were generally well tolerated with moderate adverse events, consisting mainly of transient inflammatory reactions at the virus injection sites. Among the 30 melanoma patients assessable for tumor response, a partial response was observed in one patient, and disease stabilization in two others. The remaining patients had progressive disease. Among the patients with stable or progressive disease, five showed evidence of tumor regression. A CTL response against the MAGE-3 vaccine antigen was detected in three of four patients with tumor regression, and in only one of 11 patients without regression. Conclusion Repeated vaccination with ALVAC miniMAGE-1/3 is associated with tumor regression and with a detectable CTL response in a minority of melanoma patients. There is a significant correlation between tumor regression and CTL response. The contribution of vaccine-induced CTL in the tumor regression process is discussed in view of the immunologic events that could be analyzed in detail in one patient.

Published
2005

26. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

Author

UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Kruit, WHJ, Van Ojik, Heidi H., Brichard, Vincent G., Escudier, B, Dorval, T, Dréno, B., Patel, P, van Baren, Nicolas, Avril, Marie-Françoise, Piperno, S, Khammari, A, Stas, M., Ritter, G., LETHE, Bernard, GODELAINE, Danièle, Brasseur, Francis, Zhang, Yi, van der Bruggen, Pierre, Boon, Thierry, Eggermont, AMM, Marchand, Marie, UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Kruit, WHJ, Van Ojik, Heidi H., Brichard, Vincent G., Escudier, B, Dorval, T, Dréno, B., Patel, P, van Baren, Nicolas, Avril, Marie-Françoise, Piperno, S, Khammari, A, Stas, M., Ritter, G., LETHE, Bernard, GODELAINE, Danièle, Brasseur, Francis, Zhang, Yi, van der Bruggen, Pierre, Boon, Thierry, Eggermont, AMM, and Marchand, Marie

Abstract

The purpose of this phase 1/2 study was to evaluate toxicity, tumor evolution and immunologic response following administration of a fixed dose of a recombinant MAGE-3 protein by subcutaneous and intradermal routes in the absence of immunologic adjuvant. Thirty-two patients with detectable metastatic melanoma expressing gene MAGE-3 were included and 30 received at least one injection with a fixed dose of a ProtD-MAGE-3 fusion protein. The immunization schedule included 6 intradermal and subcutaneous injections at 3-week intervals. Afterward, patients without major tumor progression who required other treatments received additional vaccinations at increasing time intervals. The vaccine was generally well tolerated. Among the 26 patients who received at least 4 vaccinations, we observed 1 partial response and 4 mixed responses. For these 5 responding patients, time to progression varied from 3.5 to 51+ months. An anti-MAGE-3 CD4 T-lymphocyte response was detected in 1 out of the 5 responding patients. The majority of patients had no anti-MAGE-3 antibody response. The clinical and immunologic responses generated by the vaccine are rather limited. Nevertheless, given the potential antitumor efficacy and the very mild toxicity of vaccinations, further studies combining MAGE proteins and/or peptides with potent immunologic adjuvants are warranted, not only in metastatic melanoma, but also in the adjuvant setting. (c) 2005 Wiley-Liss, Inc.

Published
2005

45. Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: Results from Institut Curie protocols 1977–1987 and two consecutive French multicenter trials Pegase 02 (1995–96) and Pegase 05 (1997–99)

Author

Palangie, T., primary, Viens, P., additional, Roché, H., additional, Beuzeboc, P., additional, Dieras, V., additional, Dorval, T., additional, Pierga, J.-Y., additional, Mosseri, V., additional, Asselain, B., additional, and Pouillart, P., additional

Published
2004
Full Text
View/download PDF

47. Bias Image Correction Via Stationarity Maximization.

Author

Hutchison, David, Kanade, Takeo, Kittler, Josef, Kleinberg, Jon M., Mattern, Friedemann, Mitchell, John C., Naor, Moni, Nierstrasz, Oscar, Pandu Rangan, C., Steffen, Bernhard, Sudan, Madhu, Terzopoulos, Demetri, Tygar, Doug, Vardi, Moshe Y., Weikum, Gerhard, Ayache, Nicholas, Ourselin, Sébastien, Maeder, Anthony, Dorval, T., and Ogier, A.

Abstract

Automated acquisitions in microscopy may come along with strong illumination artifacts due to poor physical imaging conditions. Such artifacts obviously have direct consequences on the efficiency of an image analysis algorithm and on the quantitative measures. In this paper, we propose a method to correct illumination artifacts on biological images. This correction is based on orthogonal polynomial modeling, combined with stationary maximization criteria. To validate the proposed method we show that we improve particle detection algorithm. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

48. Cutaneous melanoma

Author

Négrier, S, primary, Fervers, B, additional, Bailly, C, additional, Beckendorf, V, additional, Cupissol, D, additional, Doré, J F, additional, Dorval, T, additional, Garbay, J R, additional, and Vilmer, C, additional

Published
2001
Full Text
View/download PDF

49. Facteurs de risque et étude bactériologique d'une épidémie de diarrhée à Clostridium difficile dans un service d'oncologie adulte

Author

Blot, E., primary, Escande, M.C., additional, Grandpeix, C., additional, Barbut, F., additional, Asselain, B., additional, Falcou, M.C., additional, Girre, V., additional, Pierga, J.Y., additional, Dieras, V., additional, Palangie, T., additional, Dorval, T., additional, Jouve, M., additional, and Pouillart, P., additional

Published
2000
Full Text
View/download PDF

50. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

Author

Tartour, E, primary, Mehtali, M, additional, Sastre-Garau, X, additional, Joyeux, I, additional, Mathiot, C, additional, Pleau, J M, additional, Squiban, P, additional, Rochlitz, C, additional, Courtney, M, additional, Jantscheff, P, additional, Herrmann, R, additional, Pouillart, P, additional, Fridman, W H, additional, and Dorval, T, additional

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results